• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
May 29, 2019 07:01 AM EDTUpdated 07:44 AM
R&D
Pharma

Lit­tle Cara steers through their first pos­i­tive PhI­II with a ‘break­through’ drug and a path to the FDA

John Carroll

Editor & Founder

Cara Ther­a­peu­tics $CARA has suc­cess­ful­ly hit a key mile­stone in its push to get their lead drug across the fin­ish line at the FDA. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • The Trump ad­min­is­tra­tion is pro­mot­ing wear­able health de­vices — with or with­out ev­i­dence July 3, 2025
  • 4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans July 3, 2025
  • Dizal’s lung can­cer pill ap­proval sets up com­pe­ti­tion with J&J July 3, 2025
TRENDING NOW

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

HHS ac­tions to re­move web con­tent were ar­bi­trary, 'poor­ly thought-through,' judge rules

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times